Chardan analyst Geulah Livshits lowered the firm’s price target on Iovance Biotherapeutics (IOVA) to $25 from $30 and keeps a Buy rating on the shares after the company reported Q1 results and lowered its FY25 product revenue view to $250M-$300M from $450M-$475M based on launch dynamics. The firm is updating its model for the revised launch projections and Q1 financials, the analyst noted.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IOVA:
- Iovance price target lowered to $20 from $32 at H.C. Wainwright
- Iovance downgraded to Market Perform from Outperform at Citizens JMP
- Iovance Biotherapeutics Reports Q1 2025 Financial Results
- Iovance Biotherapeutics: Buy Rating Amid Signs of Recovery and Growth Potential
- Closing Bell Movers: Pinterest jumps 15%, Toast up 7% after earnings